Semaglutide
Semaglutide Peptide
A GLP-1 receptor agonist peptide that regulates appetite and blood sugar. The active pharmaceutical ingredient in Ozempic and Wegovy, also available as research peptide.
Typical Cost
$900-1400/month (brand), $149-400/month (compounded)
Status
Research
Peptide Profile
Semaglutide
Mechanism of Action
Mimics GLP-1 hormone, stimulating insulin secretion in response to glucose, suppressing glucagon, delaying gastric emptying, and acting on hypothalamic appetite centers to reduce hunger.
Common Dosages
subcutaneous
0.25-2.4mg
Weekly · Ongoing
Benefits
Significant weight loss
Improved glycemic control
Reduced cardiovascular risk
Appetite suppression
Better portion control
Sustained energy
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
Gallbladder issues
Pancreatitis risk
Key Research
STEP 1 Trial - Semaglutide 2.4mg
Average 14.9% weight loss at 68 weeks in adults with obesity
SUSTAIN 6 - Cardiovascular outcomes
Significant reduction in major adverse cardiovascular events in type 2 diabetes patients
Regulatory Status
FDA-approved (Ozempic for diabetes, Wegovy for weight loss). Also available as research peptide from compounding pharmacies (503A/503B).
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
- ⚠Personal/family history of pancreatitis
SeraVia Gut+ Balance helps manage semaglutide-induced nausea, while Muscle+ Protect supports lean mass during rapid weight loss.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.